Posted 27 June 2017
By Pallavi Trivedi
This article presents the contrasting views and continuing debate among health authorities in Australia, Canada, Europe, Japan and the US as well as industry experts regarding conventions for naming biological products and biosimilars. It discusses the World Health Organization's (WHO's) proposal for naming and the importance of a clear distinction between the drugs to avoid confusion and ensure patient safety.
Share this article:
Categories: Biologics and biotechnology, Submission and registration, News, US, Canada, Europe, Asia, Oceania, FDA, EMA, Health Canada, PMDA, TGA, WHO
Tags: Biosimilars, Biosimilar Naming, Biological Qualifier, INN